Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Eosinophilic fasciitis Indication Strategy Report 2026: IL-5, Trials and Deals
23 July 2026
2026 Eosinophilic fasciitis strategy: epidemiology, IL-5 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Morphea Indication Strategy Report 2026: TGF-beta, Trials and Deals
23 July 2026
2026 Morphea strategy: epidemiology, TGF-beta biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Discoid lupus erythematosus Indication Strategy Report 2026: TYK2, Trials and Deals
23 July 2026
2026 Discoid lupus erythematosus strategy: epidemiology, TYK2 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Cutaneous lupus erythematosus Indication Strategy Report 2026: IFNAR1, Trials and Deals
23 July 2026
2026 Cutaneous lupus erythematosus strategy: epidemiology, IFNAR1 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Autoimmune pancreatitis Indication Strategy Report 2026: CD20, Trials and Deals
23 July 2026
2026 Autoimmune pancreatitis strategy: epidemiology, CD20 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Autoimmune gastritis Indication Strategy Report 2026: BAFF, Trials and Deals
23 July 2026
2026 Autoimmune gastritis strategy: epidemiology, BAFF biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Pernicious anemia Indication Strategy Report 2026: BAFF, Trials and Deals
23 July 2026
2026 Pernicious anemia strategy: epidemiology, BAFF biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Autoimmune neutropenia Indication Strategy Report 2026: FcRn, Trials and Deals
23 July 2026
2026 Autoimmune neutropenia strategy: epidemiology, FcRn biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Acquired hemophilia A Indication Strategy Report 2026: FVIII, Trials and Deals
23 July 2026
2026 Acquired hemophilia A strategy: epidemiology, FVIII biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Thrombotic thrombocytopenic purpura Indication Strategy Report 2026: ADAMTS13, Trials and Deals
23 July 2026
2026 Thrombotic thrombocytopenic purpura strategy: epidemiology, ADAMTS13 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Cold agglutinin disease Indication Strategy Report 2026: C1s, Trials and Deals
23 July 2026
2026 Cold agglutinin disease strategy: epidemiology, C1s biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Evans syndrome Indication Strategy Report 2026: FcRn, Trials and Deals
23 July 2026
2026 Evans syndrome strategy: epidemiology, FcRn biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…